Efficacy Of Potassium Magnesium Aspartate (Panangin) To Treat Liver Diseases

Objective: To study the efficacy and safety of Potassium Magnesium Aspartate (Panangin) to treat liver diseases. Methods: Two hundred and seventy-eight patients with acute or chronic liver diseases were randomly divided into control group (n=128) and Panangin treatment group (n=150). Patients in control group were treated with Glucurolactone alone, patients in treatment group were treated with Glucurolactone and Panangin. All patients were observed before, 2 weeks and 4 weeks after the treatment in terms of symptoms, liver function test including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), albumin and globulin levels, blood urea nitrogen, serum potassium and magnesium levels. Results: Panangin treatment was more efficient to decrease the elevated ALT, AST and TBil levels (P<0.05 or 0.01). The total efficacy rate was higher in Panangin group than in control group ( 2 weeks: 72.00% vs 60.94%, P=0.0252; 4 weeks: 89.33% vs 71.87%, P=0.0004 ). Conclusion: Panangin is a safe and efficient drug to treat acute and chronic liver diseases.